Mocravimod (KRP-203) hydrochloride is a S1P1 and S1P4 receptors agonist with EC50 of 1 nM and 10 nM, respectively.
|Source||Arterioscler Thromb Vasc Biol (2013). Figure 3. KRP-203|
|Cell Lines||LDL-R-/- mice|
|Incubation Time||16 weeks|
|Results||In addition, reduced production of interleukin (IL)-2 and interferon (IFN)-γ, 2 cytokines released from activated CD4+ T cells in response to concanavalin A or phytohaemagglutinin, was noted in splenocytes obtained from KRP-203–treated mice|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO 10 mM|
|Related S1P Receptor Products|
Etrasimod (APD334) is a specific and orally available antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor, with IC50 of 1.88 nM in CHO cells.
PF-543 Citrate is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC50 of 2 nM and a Ki of 3.6 nM.
Opaganib (ABC294640) is a selective and competitive SK2 inhibitor with a Ki of 9.8 μM.
NIBR-0213 is an orally active, potent and S1P1-selective sphingosine 1-phosphate (S1P) receptor antagonist.
A-971432 is an orally bioavailable, non-clastogenic, azetidinecarboxylate compound that acts as a highly potent and selective sphingosine-1-phosphate receptor 5 agonist (IC50 = 6 nM/S1P5, 362 nM/S1P1 and >10 μM/S1P3 in a radio-ligand binding assay).
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.